With this result, and considering that KRAS/STK11-mutant lung cancer displays key differences in tumor associated immune cells as compared to other molecular subtypes and poorer response to immune checkpoint blockade (Skoulidis et al. 2015; Rosellini et al. 2022; Judd et al. 2021; Koyama et al. 2016), we assessed PD-L1 expression (encoded by the gene CD274) between the High PER1 and Low PER1 and the High PER1 and Low PER1 lung cancer patient cohorts. The gene discussed is CD274; the disease is neoplasm.